Final Operational Milestone #5

During this reporting period, Capricor has reached it’s final milestone with the completion of study enrollment, treatment and follow-up of all eligible subjects participating in the HOPE Open Label Extension trial. All subjects received two doses of the CAP-1002 product and completed the 6-month observation period per the clinical protocol.